IT | 2017-03-21
6WIND Announces Next Generation Security Gateway for Mobile Operators to Secure and Scale 4G and 5G Network Infrastructure

IPsec VPN Software Available Today with Unrivaled Performance for Bare Metal and Virtual Machine Deployments on COTS Servers

Santa Clara, CA, March 21, 2017 – 6WIND, a high-performance networking software company, today announced its Next Generation Security Gateway solution for 4G and 5G mobile infrastructure. Available immediately, the solution is based on 6WIND Turbo IPsec™ software, a widely deployed product in mobile and fixed telecom infrastructure for 4G/LTE. 6WIND Turbo IPsec provides high performance IPsec VPNs on Commercial-off-the-Shelf (COTS) servers, at a fraction of legacy hardware system costs. 6WIND Turbo IPsec can be deployed bare metal or in a virtual machine with the same functionalities and performance, enabling a seamless transition to virtualization and NFV.

With the 4G/5G data and voice convergence to single IP-based networks, new security and performance challenges arise. The mobile infrastructure, specifically the mobile backhaul, must meet these performance challenges and protect against the new threats linked to untrusted IP networks, while controlling costs. Operators are also transitioning to virtualization to further decrease costs while increasing service flexibility and optimizing their return on investment.

6WIND’s Next Generation Security Gateway (SeGW) solution addresses these challenges with the following benefits:

  • Security Performance: Linear scalability of performance regardless of deployment configuration (bare metal or virtualized).
    • 12 Gbps of encrypted IPsec traffic per core reaching more than 100 Gbps on a single Intel processor
    • Up to 100,000 IKE tunnels with 1,000 tunnels establishment per second
    • Traffic loads scale across 10, 40 and 100G connectivity
  • Virtualization Readiness: Complete virtualized SeGW appliance with support for Linux KVM, VMware ESXi and Microsoft Hyper-V hypervisors.
  • High Availability: Link failure detection and failover mechanisms, combined with IPsec session synchronization, to eliminate single points of failure and enable local and geo redundancy without service interruption.
  • Management and Monitoring: Operational Support Systems (OSS) and Management and Orchestration (MANO) integration for network management and monitoring.

“At 6WIND, we provide high performance software that allows standard servers to rival specialized hardware systems for all size network deployments,” said Eric Carmès, CEO and Founder of 6WIND. “6WIND software is available today as a cost-effective alternative with high performance virtualization options so that mobile operators can scale and secure their 4G and 5G infrastructure without expensive hardware prices.”

Demonstration at MPLS + SDN + NFV World, Paris, March 21 – 24

We will demonstrate 6WIND’s Next Generation Security Gateway solutions for 4G/5G mobile infrastructure security in our booth #302 along with additional solutions for secure site-to-site VPNs. 6WIND CEO and Founder Eric Carmès will also present 6WIND’s security solutions during his speech on March 23, Track 2, at 12:20 pm CET.

Additional Resources

6WIND Solution Brief for Mobile Infrastructure Security.

6WIND Demo Video for Mobile Infrastructure Security.

About 6WIND

6WIND’s networking software solves performance and time-to-market challenges for OEMs and Network Builders. The company’s packet processing software and software appliances are optimized for cost-effective hardware, such as Commercial-off-the-Shelf (COTS) servers, with a choice of multicore processors to deliver a wide variety of networking and security protocols and features. 6WIND is based near Paris, France with regional offices in China, South Korea and the United States. For more information, visit


Silver Economie | 2017-03-14
Sanofi and Voluntis Announce a Global Alliance to Deliver Digital Insulin Titration Solutions for People with Type 2 Diabetes

Paris, France - March 14, 2017 – Sanofi and Voluntis announced today a non-exclusive agreement to deliver digital insulin titration solutions, featuring a mobile phone application designed to help improve decision-making and self-management of type 2 diabetes for people treated with basal insulin. The application will also enable remote monitoring by health care teams. The agreement reinforces the existing alliance between the two companies, established in 2011, by expanding both its scope and geography.

The alliance will leverage Sanofi's expertise in bringing innovative treatments to people living with diabetes and Voluntis’ experience in creating companion software. Sanofi and Voluntis will launch pilot programs using the mobile phone application in North America and several European countries. The application received FDA clearance and the CE mark in 2016. 

Sanofi and Voluntis have worked together over several years to develop innovative digital solutions. Their alliance began in 2011 with the development of Diabeo®, a software medical device that helps people with diabetes in France to manage their basal-bolus treatment. 

“We are delighted to expand our long-standing collaboration with Sanofi,” said Eric Elliott, Chairman of Voluntis and former CEO of Prime Therapeutics. “This new phase of our partnership with a world leader in diabetes will help us deliver digital titration tools into the hands of providers and their patients. Furthermore, digital therapeutics allow manufacturers and payers to check whether agreed value metrics have been achieved and help to lower costs without compromising on patient outcomes and access. They ensure that prescription medications deliver the effects for which they were brought to market. 

“Despite the availability of new medicines for the treatment of diabetes, we see that outcomes are not sufficiently improving and that more than half of patients are not well controlled,”1 said Peter Guenter, Executive Vice-President, Diabetes & Cardiovascular at Sanofi. “With this in mind, Sanofi is focusing on a beyond-the-pill approach. We know that diabetes management is a 24/7 job, and we recognize that the right tools need to be developed to realize better outcomes. The long-term alliance we have with Voluntis will help us to reach that goal.” 

About Diabetes

Diabetes is a chronic condition characterized by high blood sugar levels that stem from the body’s inappropriate production or use of insulin. In 2014, it was estimated that 29 million Americans2 and 422 million people worldwide3 have diabetes. About 90-95% of these individuals have type 2 diabetes and 29% take some form of insulin.4 Despite being provided with effective medications, more than half of them do not meet the recommended targets for glycemic control.5 Major contributing factors include challenges with insulin initiation and titration. Owing to the complications associated with diabetes, its total annual cost in the US amounts to $245 billion. Optimizing adherence to diabetes medications is recognized as one of the most effective ways of controlling disease expenditures.6 The cost saving opportunity in the U.S is estimated to be $4,690 per patient per year.7 

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY). 

About Voluntis

Pioneering therapeutic companion software, Voluntis innovates healthcare by embedding connectivity in therapeutics and medical intelligence in software. Dedicated to managing chronic conditions, Voluntis’ companion software aim to enable treatment personalization, to support team-care coordination and to improve real-world outcomes. Harnessing its proprietary technology, Voluntis has developed digital solutions for diabetes, cancer, anticoagulation treatments and haemophilia. Voluntis is headquartered in Paris, France, and has offices in Cambridge, MA. For more information, visit 


1. Lipska KJ et al. Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006–2013. Diabetes Care 2016 Sep; dc160985. Retrieved March 13th from

2. National Diabetes Statistics Report, 2014. (2014). Retrieved February 10, 2017, from

3. Roglic, G. (2016). Global report on diabetes. Retrieved February 10, 2017 from

4. National Diabetes Statistics Report, 2014. (2014). Retrieved February 10, 2017, from

5. Bailey CJ, Kodack M. “Patient adherence to medication requirements for therapy of type 2 diabetes.” Int J Clin Pract. 2011 Mar; 65(3):314-22.

6. National Diabetes Statistics Report, 2014. (2014). Retrieved February 10, 2017, from

7. Diabetes Care Value Program Guarantees More Affordable, Higher-Quality Diabetes Care. Express Scripts. Sep 1, 2016.

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi’s ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2016. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.



Last News

6WIND Announces Next Generation Security Gateway for Mobile Operators to Secure and Scale 4G and 5G Network Infrastructure

Sanofi and Voluntis Announce a Global Alliance to Deliver Digital Insulin Titration Solutions for People with Type 2 Diabetes
Legal informationrealisation digitalcube